A study linking Indian-made generic drugs to a higher risk of serious side effects in the US has drawn backlash from the industry’s most influential lobby group, as India moves to defend its dominant market share amid trade tensions under President Donald Trump.
The study, which analyzed more than 2,400 drugs sold in the US between 2009 and 2018, found that Indian generics were associated with a 54% greater risk of serious adverse events — including hospitalization, disability, and death — compared with equivalent domestically made medicines. The research links operations and supply chain issues in the manufacturing process as ...